Revelation Biosciences, Inc.
REVB Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.79
KIRA · Stoqly’s AI analyst, in plain words
- Revelation Biosciences, Inc. lost $8.9M in fiscal 2025.
Market cap
$14.5M
P/E
0.1x
Revenue
—
Net income
−$8.9M
Free cash flow
—
Operating margin
—
Revelation Biosciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$8.9M
No. It lost money last year.
How is the share priced?
0.1x
One share costs 0.1 times its yearly profit per share.
What Revelation Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- REVELATION BIOSCIENCES, INC.
- CIK
- 0001810560
Revelation Biosciences, Inc. · REVB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$12.0M | −$10.8M | −$0.1M | −$15.0M | −$8.9M |
| Diluted EPS | −$42.50 | −$149.20 | −$8.44 | −$1,052.16 | −$23.95 |
| Cash | |||||
| Cash from operations | −$11.1M | −$11.2M | −$7.3M | −$18.3M | −$8.3M |
| Capital expenditure | $0.1M | — | — | $0.0M | — |
| Free cash flow | −$11.2M | — | — | −$18.3M | — |
| Share buybacks | $35.5M | — | — | — | — |
| Share count change | −88.3% | −74.3% | −80.4% | 0.7% | 4,241.3% |
| Debt and strength | |||||
| Cash and short-term investments | $1.3M | $5.3M | $12.0M | $6.5M | $10.7M |
| Shareholders' equity | −$0.1M | $1.1M | $6.6M | $4.7M | $8.9M |
| Current ratio | 0.9x | 1.2x | 2.2x | 3.4x | 5.4x |
| Interest coverage | −285.9x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −723.8% | −2,272.7% | −3.1% | −264.9% | −131.4% |
| Return on tangible equity | — | −1,028.9% | −1.8% | −319.4% | −167.8% |
| Altman Z'' | −63.3 | −26.9 | −6.8 | −20.8 | −10.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Revelation Biosciences, Inc. · REVB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.79 a share, the company is worth $14.5M: 0.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001810560). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.